by Savitha C Muppala on  April 1, 2011 at 8:30 PM Corporate News
 Glenmark and GBR401
The discovery and initiated IND enabling studies of a Novel Biological Entity (NBE) lead candidate, GBR401 and anti-CD19 monoclonal antibody, has been announced by Glenmark Pharmaceuticals SA (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals India.

The brain-child of Glenmark's Biologics Research Centre, GBR 401 helps in targeting diseases like lymphomas and leukemia's of B-cell origin.



Source: Medindia

Most Popular on Medindia